Constantine E. Anagnostopoulos, Ph.D.- Chairman
Managing General Partner,
Gateway Venture Partners LP
 
Dr. Anagnostopoulos has served as Chair since 2001. He is Managing General Partner of Gateway Venture Partners, and also serves as Chairman of Metaphore Pharmaceuticals and on the boards of a number of other biotechnology companies, including Dyax and Genzyme. Dr. Anagnostopoulos is a retired officer of Monsanto Company, where he also served as Director of R&D, general manager of a number of operating divisions and Chairman, President and Chief Executive Officer of Monsanto Europe-Africa. As Head of Monsanto’s New Enterprise Division, he was the architect of Monsanto’s pioneering activities in corporate venture capital and served as President and Chief Executive Officer of Monsanto Venture Capital Company. Dr. Anagnostopoulos holds a Ph.D. in Organic Chemistry from Harvard University and over 20 patents in Organic and Polymer Chemistry.
top of page

Robert A. Beardsley, Ph.D.
President and Chief Executive Officer
 
Dr. Beardsley has served as Kereos’ President and CEO, and as a board member, since January 2003. Prior to joining Kereos, Dr. Beardsley was acting CEO and a Board member of Metaphore Pharmaceuticals where he played key roles in two successful private equity fundraising rounds. In addition, he is the cofounder and former Managing Member of SImile Investors, LLC., and has held a number of positions in biotechnology and life science related firms, including bioStrategies Group and Vector Securities International. Dr. Beardsley currently serves on the boards of Collagenex Pharmaceuticals, BioSeek and PharmaMonde. He holds a Ph.D. in Biochemical Engineering and a B.S.Ch.E. from the University of Iowa, along with an M.B.A. in Finance from the University of Chicago.
top of page

Gregory Johnson, Ph.D.
Managing Director, Prolog Ventures
 
Dr. Johnson joined Kereos as a Director in September of 2005 bringing with him over two decades of venture capital experience.  Prior to joining Prolog, he was Vice President of Monsanto Venture Capital and Monsanto’s director of new ventures and technology where he oversaw Monsanto’s $80 million portfolio of corporate venture investments.  Dr. Johnson also spent 14 years as a general partner at Gateway Associates, a St. Louis-based venture capital company with more than $180 million in total funds under management.  Besides Kereos, he also sits on the Boards of Everest, Singulex, and Stereotaxis.  Dr Johnson holds a doctoral degree in physics from the University of Rochester and a bachelor’s degree from MIT.
top of page

Michael D. Loberg, Ph.D.
Independent
 
Dr. Loberg joined Kereos as a board member in January 2004. He recently served as President and CEO of NitroMed, and also on the board of Advanced Magnetics. In 2003 Dr. Loberg oversaw and led NitroMed’s initial public offering process. Previously, Dr. Loberg spent nearly 20 years with the Bristol-Myers Squibb (BMS) organization, most recently as President, BMS Oncology & Immunology. He also served as President, BMS Primary Care division; President, BMS Northern Europe; President, BMS Specialty Pharmaceuticals; President, Squibb Diagnostics; and Vice President for Diagnostic R&D, E.R. Squibb & Sons. Prior to BMS, Dr. Loberg served as Associate Professor in the University of Maryland Schools of Pharmacy and Medicine. He holds a Ph.D. in Chemistry from Washington University.
top of page

Thomas C. Melzer
Managing Director, RiverVest Venture Partners

Mr. Melzer joined as a board member in 2001. He is Managing Director and a founder of RiverVest Venture Partners, and also serves on the boards of Centerre Healthcare, Isto Technologies and the Federal Farm Credit Banks Funding Corporation. Previously, he was the President and CEO of the Federal Reserve Bank of St. Louis and served on the Federal Open Market Committee (FOMC). Before joining the Fed, Mr. Melzer was a Managing Director of Morgan Stanley & Co. Mr. Melzer holds an M.B.A. and a B.S. in Electrical Engineering from Stanford University.
top of page

John Rice, Ph.D.
Managing Partner, Triathlon Medical Ventures
 
Dr. Rice was appointed as a Kereos director in September 2005.  Previous to joining Triathlon Medical Ventures, he was a Managing Director at Senmed Medical Ventures and served as a member of the investment committee.  In addition to his investment experience, Dr. Rice spent 13 years with Battelle Memorial Institute in various capacities, including overseeing Battelle’s international biotechnology activities.  Other boards he serves on include Bio/Start and Omeris.  Dr. Rice earned a BS in Microbiology, as well as M.S. and Ph.D. degrees in Microbiology and Virology from The Ohio State University.
top of page

Fred M. Schwarzer , J.D.
Managing Partner, Charter Life Sciences

Mr. Schwarzer joined the board in 2007. Prior to founding Charter Life Sciences, Mr. Schwarzer was the chief executive officer and then chairman of Heska (HSKA), where he completed major corporate partnership and acquisitions and Heska’s initial public offering and follow-on public offering. Mr. Schwarzer served as president and CEO of Mingly Capital Corporation, which focused on developing cross-border opportunities in life sciences and information technology. He was a senior vice president of C.M. Capital, a diversified asset management company. Mr. Schwarzer founded General Counsel Associates, and was a partner with Pillsbury, Madison & Sutro. Mr. Schwarzer received a J.D. from the University of California, Berkeley, Boalt Hall School of Law and a B.A. from the University of Michigan.
top of page

Samuel A. Wickline, M.D.
Professor of Medicine, Physics and Biomedical Engineering, Washington University
Co-Director of Cardiovascular Division, Washington University School of Medicine
 
Dr. Wickline is a founder of Kereos and Chair of the Scientific Advisory Board, and has served as a board member since inception. He is Co-Director of the Cardiovascular Division of the Washington University School of Medicine (WUSM) and Professor of Medicine, Physics, Biomedical Engineering, and Cell Biology at WU. Dr. Wickline’s investigative work has focused on molecular imaging and targeted therapy of cardiovascular disease, as well the use of magnetic resonance and ultrasonic tissue characterization of heart and vascular tissues, and he is the author of over 150 publications in these and related fields. He holds an M.D. degree from the University of Hawaii.
top of page